anti traf6 Search Results


93
Bioss traf6 rb
(A) Co-staining of IRAK1 clusters and proteasome in iBMDMs. Kdo-2 Lipid A and P3C co-treatment (50 nM). Scale Bar: 10 μ . (B) Dose response of IRAK1 clustering in iBMDMs with Kdo-2 Lipid A and P3C ± 2h pre-treatment with 4uL of monensin, BD GolgiStop™ for every 3 mL of cell culture. (C-K) Kdo-2 Lipid A and P3C co-treatment (50 nM) in iBMDMs. Co-staining of IRAK1 clusters and (C) MyD88, (D) TICAM2, (E) IRAK4, (F) IRAK2, (G) <t>TRAF6</t> and (H) pTBK1. Scale Bar: 10 μ . (I) Summary of IRAK1 clustering with TLR signaling components. ND: Not Determined. (J-L) IRAK1 clustering in iBMDMs 0, 2 and 3h post-treatment with 50 nM Kdo-2 Lipid A and P3C ± 30 min pre-treatment with (J) dynasore, an internalization inhibitor (20 μ M); (K) ST2825, a MyD88 dimerization inhibitor (20 μ M); and (L) thymoquinone, an IRAK1 kinase inhibitor (25 μ M). (Panels B, J-L) Data are represented as median ± MAD. (Panels J-L) Unpaired t test with Holm-Šídák’s correction. p = 0.1234 (ns), 0.0332(*); 0.0021 (**); 0.0002 (***); < 0.0001 (****). Data shown are representative of at least two independent experiments. See also supporting .
Traf6 Rb, supplied by Bioss, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+traf6/TRAF6+Polyclonal+Antibody/bio_rxiv__2019__12__26__888776-272-12-14
Average 93 stars, based on 1 article reviews
traf6 rb - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

90
Bio-Techne corporation traf-6 antibody
(A) Co-staining of IRAK1 clusters and proteasome in iBMDMs. Kdo-2 Lipid A and P3C co-treatment (50 nM). Scale Bar: 10 μ . (B) Dose response of IRAK1 clustering in iBMDMs with Kdo-2 Lipid A and P3C ± 2h pre-treatment with 4uL of monensin, BD GolgiStop™ for every 3 mL of cell culture. (C-K) Kdo-2 Lipid A and P3C co-treatment (50 nM) in iBMDMs. Co-staining of IRAK1 clusters and (C) MyD88, (D) TICAM2, (E) IRAK4, (F) IRAK2, (G) <t>TRAF6</t> and (H) pTBK1. Scale Bar: 10 μ . (I) Summary of IRAK1 clustering with TLR signaling components. ND: Not Determined. (J-L) IRAK1 clustering in iBMDMs 0, 2 and 3h post-treatment with 50 nM Kdo-2 Lipid A and P3C ± 30 min pre-treatment with (J) dynasore, an internalization inhibitor (20 μ M); (K) ST2825, a MyD88 dimerization inhibitor (20 μ M); and (L) thymoquinone, an IRAK1 kinase inhibitor (25 μ M). (Panels B, J-L) Data are represented as median ± MAD. (Panels J-L) Unpaired t test with Holm-Šídák’s correction. p = 0.1234 (ns), 0.0332(*); 0.0021 (**); 0.0002 (***); < 0.0001 (****). Data shown are representative of at least two independent experiments. See also supporting .
Traf 6 Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+traf6/TRAF-6+Antibody/bio-techne+corporation___nb100-56179
Average 90 stars, based on 1 article reviews
traf-6 antibody - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

94
Boster Bio a00185
(A) Co-staining of IRAK1 clusters and proteasome in iBMDMs. Kdo-2 Lipid A and P3C co-treatment (50 nM). Scale Bar: 10 μ . (B) Dose response of IRAK1 clustering in iBMDMs with Kdo-2 Lipid A and P3C ± 2h pre-treatment with 4uL of monensin, BD GolgiStop™ for every 3 mL of cell culture. (C-K) Kdo-2 Lipid A and P3C co-treatment (50 nM) in iBMDMs. Co-staining of IRAK1 clusters and (C) MyD88, (D) TICAM2, (E) IRAK4, (F) IRAK2, (G) <t>TRAF6</t> and (H) pTBK1. Scale Bar: 10 μ . (I) Summary of IRAK1 clustering with TLR signaling components. ND: Not Determined. (J-L) IRAK1 clustering in iBMDMs 0, 2 and 3h post-treatment with 50 nM Kdo-2 Lipid A and P3C ± 30 min pre-treatment with (J) dynasore, an internalization inhibitor (20 μ M); (K) ST2825, a MyD88 dimerization inhibitor (20 μ M); and (L) thymoquinone, an IRAK1 kinase inhibitor (25 μ M). (Panels B, J-L) Data are represented as median ± MAD. (Panels J-L) Unpaired t test with Holm-Šídák’s correction. p = 0.1234 (ns), 0.0332(*); 0.0021 (**); 0.0002 (***); < 0.0001 (****). Data shown are representative of at least two independent experiments. See also supporting .
A00185, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+traf6/Anti-TRAF6+Antibody+Picoband/pm41605925-268-22-21
Average 94 stars, based on 1 article reviews
a00185 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

94
Boster Bio factor 6 traf6 antibody
(A) Co-staining of IRAK1 clusters and proteasome in iBMDMs. Kdo-2 Lipid A and P3C co-treatment (50 nM). Scale Bar: 10 μ . (B) Dose response of IRAK1 clustering in iBMDMs with Kdo-2 Lipid A and P3C ± 2h pre-treatment with 4uL of monensin, BD GolgiStop™ for every 3 mL of cell culture. (C-K) Kdo-2 Lipid A and P3C co-treatment (50 nM) in iBMDMs. Co-staining of IRAK1 clusters and (C) MyD88, (D) TICAM2, (E) IRAK4, (F) IRAK2, (G) <t>TRAF6</t> and (H) pTBK1. Scale Bar: 10 μ . (I) Summary of IRAK1 clustering with TLR signaling components. ND: Not Determined. (J-L) IRAK1 clustering in iBMDMs 0, 2 and 3h post-treatment with 50 nM Kdo-2 Lipid A and P3C ± 30 min pre-treatment with (J) dynasore, an internalization inhibitor (20 μ M); (K) ST2825, a MyD88 dimerization inhibitor (20 μ M); and (L) thymoquinone, an IRAK1 kinase inhibitor (25 μ M). (Panels B, J-L) Data are represented as median ± MAD. (Panels J-L) Unpaired t test with Holm-Šídák’s correction. p = 0.1234 (ns), 0.0332(*); 0.0021 (**); 0.0002 (***); < 0.0001 (****). Data shown are representative of at least two independent experiments. See also supporting .
Factor 6 Traf6 Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+traf6/Anti-TRAF6+Antibody/10__1016_slash_j__dcmed__2022__10__008-56-39-43
Average 94 stars, based on 1 article reviews
factor 6 traf6 antibody - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

90
MBL Life science polyclonal rabbit anti-traf2 ab
(A) Co-staining of IRAK1 clusters and proteasome in iBMDMs. Kdo-2 Lipid A and P3C co-treatment (50 nM). Scale Bar: 10 μ . (B) Dose response of IRAK1 clustering in iBMDMs with Kdo-2 Lipid A and P3C ± 2h pre-treatment with 4uL of monensin, BD GolgiStop™ for every 3 mL of cell culture. (C-K) Kdo-2 Lipid A and P3C co-treatment (50 nM) in iBMDMs. Co-staining of IRAK1 clusters and (C) MyD88, (D) TICAM2, (E) IRAK4, (F) IRAK2, (G) <t>TRAF6</t> and (H) pTBK1. Scale Bar: 10 μ . (I) Summary of IRAK1 clustering with TLR signaling components. ND: Not Determined. (J-L) IRAK1 clustering in iBMDMs 0, 2 and 3h post-treatment with 50 nM Kdo-2 Lipid A and P3C ± 30 min pre-treatment with (J) dynasore, an internalization inhibitor (20 μ M); (K) ST2825, a MyD88 dimerization inhibitor (20 μ M); and (L) thymoquinone, an IRAK1 kinase inhibitor (25 μ M). (Panels B, J-L) Data are represented as median ± MAD. (Panels J-L) Unpaired t test with Holm-Šídák’s correction. p = 0.1234 (ns), 0.0332(*); 0.0021 (**); 0.0002 (***); < 0.0001 (****). Data shown are representative of at least two independent experiments. See also supporting .
Polyclonal Rabbit Anti Traf2 Ab, supplied by MBL Life science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+traf6/anti+traf6/pm17202327-52-0-6
Average 90 stars, based on 1 article reviews
polyclonal rabbit anti-traf2 ab - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Enzo Biochem rabbit anti-traf6
(A) Co-staining of IRAK1 clusters and proteasome in iBMDMs. Kdo-2 Lipid A and P3C co-treatment (50 nM). Scale Bar: 10 μ . (B) Dose response of IRAK1 clustering in iBMDMs with Kdo-2 Lipid A and P3C ± 2h pre-treatment with 4uL of monensin, BD GolgiStop™ for every 3 mL of cell culture. (C-K) Kdo-2 Lipid A and P3C co-treatment (50 nM) in iBMDMs. Co-staining of IRAK1 clusters and (C) MyD88, (D) TICAM2, (E) IRAK4, (F) IRAK2, (G) <t>TRAF6</t> and (H) pTBK1. Scale Bar: 10 μ . (I) Summary of IRAK1 clustering with TLR signaling components. ND: Not Determined. (J-L) IRAK1 clustering in iBMDMs 0, 2 and 3h post-treatment with 50 nM Kdo-2 Lipid A and P3C ± 30 min pre-treatment with (J) dynasore, an internalization inhibitor (20 μ M); (K) ST2825, a MyD88 dimerization inhibitor (20 μ M); and (L) thymoquinone, an IRAK1 kinase inhibitor (25 μ M). (Panels B, J-L) Data are represented as median ± MAD. (Panels J-L) Unpaired t test with Holm-Šídák’s correction. p = 0.1234 (ns), 0.0332(*); 0.0021 (**); 0.0002 (***); < 0.0001 (****). Data shown are representative of at least two independent experiments. See also supporting .
Rabbit Anti Traf6, supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+traf6/rabbit+anti+traf6/pmc03416198-47-134-138
Average 90 stars, based on 1 article reviews
rabbit anti-traf6 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
MBL International anti-mouse traf6
Exaggerated inflammatory response in miR-146a –null mice. (A and B) Serum levels of TNF (A) and IL-6 (B) in miR-146a −/− ( n = 5; KO) and WT ( n = 6) animals challenged intraperitoneally with sublethal dose of LPS (1 mg/kg). Peripheral blood was drawn at the times indicated in the graphs, and cytokine concentrations were assessed by ELISA. Results are shown as means; data are representative of two independent experiments. P-value calculations were performed using Student’s t test. (C) Kaplan-Meier survival curves of miR-146a −/− (KO) and WT mice ( n = 12 for each group) challenged with a lethal dose of LPS (35 mg/kg). Results are representative of two independent experiments. P-value calculation was performed using log-rank (Mantel-Cox) test. (D and E) Production of TNF (D) and IL-6 (E) by miR-146a −/− (KO) and WT BMDMs in response to 10 ng/ml LPS challenge. Cells were stimulated for the indicated time, and cytokine concentrations were assessed by ELISA. Data are shown as mean ± SD. Results are representative of three independent experiments. (F and G) Western blot analysis of <t>TRAF6</t> and IRAK1 protein expression in WT and miR-146a −/− (KO) BMDMs (F) and CD19 + splenic B cells (G). Numbers under the blots denote relative expression normalized to β-actin expression for each sample. Two mice per genotype were analyzed. Results are representative of two independent experiments. (H and I) Quantification of Western blots in F and G. Relative TRAF6 and IRAK1 expression in WT and KO BMDMs (H) and CD19 + splenic B cells (I) is plotted. Data from two mice for each genotype were averaged and are expressed as a ratio of protein expression in miR-146a KO to WT cells. All experiments were carried in the B6/ miR-146a −/− strain of mice.
Anti Mouse Traf6, supplied by MBL International, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+traf6/anti+traf6/pmc03173243-143-10-15
Average 90 stars, based on 1 article reviews
anti-mouse traf6 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
GeneTex primary antibodies of tumor necrosis factor receptor associated factor6 (traf6)
Exaggerated inflammatory response in miR-146a –null mice. (A and B) Serum levels of TNF (A) and IL-6 (B) in miR-146a −/− ( n = 5; KO) and WT ( n = 6) animals challenged intraperitoneally with sublethal dose of LPS (1 mg/kg). Peripheral blood was drawn at the times indicated in the graphs, and cytokine concentrations were assessed by ELISA. Results are shown as means; data are representative of two independent experiments. P-value calculations were performed using Student’s t test. (C) Kaplan-Meier survival curves of miR-146a −/− (KO) and WT mice ( n = 12 for each group) challenged with a lethal dose of LPS (35 mg/kg). Results are representative of two independent experiments. P-value calculation was performed using log-rank (Mantel-Cox) test. (D and E) Production of TNF (D) and IL-6 (E) by miR-146a −/− (KO) and WT BMDMs in response to 10 ng/ml LPS challenge. Cells were stimulated for the indicated time, and cytokine concentrations were assessed by ELISA. Data are shown as mean ± SD. Results are representative of three independent experiments. (F and G) Western blot analysis of <t>TRAF6</t> and IRAK1 protein expression in WT and miR-146a −/− (KO) BMDMs (F) and CD19 + splenic B cells (G). Numbers under the blots denote relative expression normalized to β-actin expression for each sample. Two mice per genotype were analyzed. Results are representative of two independent experiments. (H and I) Quantification of Western blots in F and G. Relative TRAF6 and IRAK1 expression in WT and KO BMDMs (H) and CD19 + splenic B cells (I) is plotted. Data from two mice for each genotype were averaged and are expressed as a ratio of protein expression in miR-146a KO to WT cells. All experiments were carried in the B6/ miR-146a −/− strain of mice.
Primary Antibodies Of Tumor Necrosis Factor Receptor Associated Factor6 (Traf6), supplied by GeneTex, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+traf6/anti+traf6/pmc06675524-57-6-22
Average 90 stars, based on 1 article reviews
primary antibodies of tumor necrosis factor receptor associated factor6 (traf6) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
BioChain Institute the anti-traf6 (ct) polyclonal antibody
Exaggerated inflammatory response in miR-146a –null mice. (A and B) Serum levels of TNF (A) and IL-6 (B) in miR-146a −/− ( n = 5; KO) and WT ( n = 6) animals challenged intraperitoneally with sublethal dose of LPS (1 mg/kg). Peripheral blood was drawn at the times indicated in the graphs, and cytokine concentrations were assessed by ELISA. Results are shown as means; data are representative of two independent experiments. P-value calculations were performed using Student’s t test. (C) Kaplan-Meier survival curves of miR-146a −/− (KO) and WT mice ( n = 12 for each group) challenged with a lethal dose of LPS (35 mg/kg). Results are representative of two independent experiments. P-value calculation was performed using log-rank (Mantel-Cox) test. (D and E) Production of TNF (D) and IL-6 (E) by miR-146a −/− (KO) and WT BMDMs in response to 10 ng/ml LPS challenge. Cells were stimulated for the indicated time, and cytokine concentrations were assessed by ELISA. Data are shown as mean ± SD. Results are representative of three independent experiments. (F and G) Western blot analysis of <t>TRAF6</t> and IRAK1 protein expression in WT and miR-146a −/− (KO) BMDMs (F) and CD19 + splenic B cells (G). Numbers under the blots denote relative expression normalized to β-actin expression for each sample. Two mice per genotype were analyzed. Results are representative of two independent experiments. (H and I) Quantification of Western blots in F and G. Relative TRAF6 and IRAK1 expression in WT and KO BMDMs (H) and CD19 + splenic B cells (I) is plotted. Data from two mice for each genotype were averaged and are expressed as a ratio of protein expression in miR-146a KO to WT cells. All experiments were carried in the B6/ miR-146a −/− strain of mice.
The Anti Traf6 (Ct) Polyclonal Antibody, supplied by BioChain Institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+traf6/the+anti+traf6++ct++polyclonal+antibody/pmc02423148-58-1-8
Average 90 stars, based on 1 article reviews
the anti-traf6 (ct) polyclonal antibody - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
MyBiosource Biotechnology anti-traf6 monoclonal antibody
Exaggerated inflammatory response in miR-146a –null mice. (A and B) Serum levels of TNF (A) and IL-6 (B) in miR-146a −/− ( n = 5; KO) and WT ( n = 6) animals challenged intraperitoneally with sublethal dose of LPS (1 mg/kg). Peripheral blood was drawn at the times indicated in the graphs, and cytokine concentrations were assessed by ELISA. Results are shown as means; data are representative of two independent experiments. P-value calculations were performed using Student’s t test. (C) Kaplan-Meier survival curves of miR-146a −/− (KO) and WT mice ( n = 12 for each group) challenged with a lethal dose of LPS (35 mg/kg). Results are representative of two independent experiments. P-value calculation was performed using log-rank (Mantel-Cox) test. (D and E) Production of TNF (D) and IL-6 (E) by miR-146a −/− (KO) and WT BMDMs in response to 10 ng/ml LPS challenge. Cells were stimulated for the indicated time, and cytokine concentrations were assessed by ELISA. Data are shown as mean ± SD. Results are representative of three independent experiments. (F and G) Western blot analysis of <t>TRAF6</t> and IRAK1 protein expression in WT and miR-146a −/− (KO) BMDMs (F) and CD19 + splenic B cells (G). Numbers under the blots denote relative expression normalized to β-actin expression for each sample. Two mice per genotype were analyzed. Results are representative of two independent experiments. (H and I) Quantification of Western blots in F and G. Relative TRAF6 and IRAK1 expression in WT and KO BMDMs (H) and CD19 + splenic B cells (I) is plotted. Data from two mice for each genotype were averaged and are expressed as a ratio of protein expression in miR-146a KO to WT cells. All experiments were carried in the B6/ miR-146a −/− strain of mice.
Anti Traf6 Monoclonal Antibody, supplied by MyBiosource Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+traf6/anti+traf6+monoclonal+antibody/pm28673093-58-27-30
Average 90 stars, based on 1 article reviews
anti-traf6 monoclonal antibody - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

86
Affinity Biosciences traf6
FHL2 interacts with <t>TRAF6</t> (A) Representative IF images of FHL2 and TRAF6 expression in kidney tissues (Scale bars, 100 μm). (B–C) The expression of TRAF6 and NF-κB pathway-related proteins in HK-2 cell lines after FHL2 overexpression was examined by Western blot. GAPDH was used as a loading control. (D) CoIP experiments validate the interaction between FHL2 and TRAF6. Data represent mean ± SDs, and statistical analysis was performed using one-way ANOVA. (∗ p < 0.05).
Traf6, supplied by Affinity Biosciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+traf6/anti+traf6/pmc13019499-7-0-2
Average 86 stars, based on 1 article reviews
traf6 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

86
Servicebio Inc traf6
FHL2 interacts with <t>TRAF6</t> (A) Representative IF images of FHL2 and TRAF6 expression in kidney tissues (Scale bars, 100 μm). (B–C) The expression of TRAF6 and NF-κB pathway-related proteins in HK-2 cell lines after FHL2 overexpression was examined by Western blot. GAPDH was used as a loading control. (D) CoIP experiments validate the interaction between FHL2 and TRAF6. Data represent mean ± SDs, and statistical analysis was performed using one-way ANOVA. (∗ p < 0.05).
Traf6, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+traf6/anti+traf6/10__1096_slash_fj__202402646r-66-25-26
Average 86 stars, based on 1 article reviews
traf6 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

Image Search Results


(A) Co-staining of IRAK1 clusters and proteasome in iBMDMs. Kdo-2 Lipid A and P3C co-treatment (50 nM). Scale Bar: 10 μ . (B) Dose response of IRAK1 clustering in iBMDMs with Kdo-2 Lipid A and P3C ± 2h pre-treatment with 4uL of monensin, BD GolgiStop™ for every 3 mL of cell culture. (C-K) Kdo-2 Lipid A and P3C co-treatment (50 nM) in iBMDMs. Co-staining of IRAK1 clusters and (C) MyD88, (D) TICAM2, (E) IRAK4, (F) IRAK2, (G) TRAF6 and (H) pTBK1. Scale Bar: 10 μ . (I) Summary of IRAK1 clustering with TLR signaling components. ND: Not Determined. (J-L) IRAK1 clustering in iBMDMs 0, 2 and 3h post-treatment with 50 nM Kdo-2 Lipid A and P3C ± 30 min pre-treatment with (J) dynasore, an internalization inhibitor (20 μ M); (K) ST2825, a MyD88 dimerization inhibitor (20 μ M); and (L) thymoquinone, an IRAK1 kinase inhibitor (25 μ M). (Panels B, J-L) Data are represented as median ± MAD. (Panels J-L) Unpaired t test with Holm-Šídák’s correction. p = 0.1234 (ns), 0.0332(*); 0.0021 (**); 0.0002 (***); < 0.0001 (****). Data shown are representative of at least two independent experiments. See also supporting .

Journal: bioRxiv

Article Title: IRAK1-mediated coincidence detection of microbial signals licenses inflammasome activation

doi: 10.1101/2019.12.26.888776

Figure Lengend Snippet: (A) Co-staining of IRAK1 clusters and proteasome in iBMDMs. Kdo-2 Lipid A and P3C co-treatment (50 nM). Scale Bar: 10 μ . (B) Dose response of IRAK1 clustering in iBMDMs with Kdo-2 Lipid A and P3C ± 2h pre-treatment with 4uL of monensin, BD GolgiStop™ for every 3 mL of cell culture. (C-K) Kdo-2 Lipid A and P3C co-treatment (50 nM) in iBMDMs. Co-staining of IRAK1 clusters and (C) MyD88, (D) TICAM2, (E) IRAK4, (F) IRAK2, (G) TRAF6 and (H) pTBK1. Scale Bar: 10 μ . (I) Summary of IRAK1 clustering with TLR signaling components. ND: Not Determined. (J-L) IRAK1 clustering in iBMDMs 0, 2 and 3h post-treatment with 50 nM Kdo-2 Lipid A and P3C ± 30 min pre-treatment with (J) dynasore, an internalization inhibitor (20 μ M); (K) ST2825, a MyD88 dimerization inhibitor (20 μ M); and (L) thymoquinone, an IRAK1 kinase inhibitor (25 μ M). (Panels B, J-L) Data are represented as median ± MAD. (Panels J-L) Unpaired t test with Holm-Šídák’s correction. p = 0.1234 (ns), 0.0332(*); 0.0021 (**); 0.0002 (***); < 0.0001 (****). Data shown are representative of at least two independent experiments. See also supporting .

Article Snippet: Antibody pairs used for PLA in iBMDMs: IRAK1 Ms (SCBT sc-5288) and TRAF6 Rb (Bioss bs-1184R); IRAK1 Ms (SCBT sc-5288) and pTBK1 Rb (CST 5483S); IRAK1 Ms (SCBT sc-5288) and pTAB2 Rb (CST 8155S); IRAK2 Ms (SCBT sc-515885) and TRAF6 Rb (Bioss bs-1184R); IRAK2 Ms (SCBT sc-515885) and pTBK1 Rb (CST 5483S); IRAK2 Ms (SCBT sc-515885) and pTAB2 Rb (CST 8155S); IRAK1 Ms (SCBT sc-5288) and ASC Rb (SCBT sc-22514-R); IRAK1 Rb (CST 4504S) and NLRP3 Ms (AdipoGen AG-20B-0014-C100).

Techniques: Staining, Cell Culture

(A-K) Kdo-2 Lipid A and P3C co-treatment (50 nM each) in iBMDMs. Co-staining of IRAK1 clusters and (A) ßTrCp, (B) pellino, and (C) IRAK3. Scale Bar: 10 μ . (D) Quantification of the Pearson’s correlation coefficient (PCC) for the correlation of TRAF6 antibody staining in IRAK1 clusters. (E) Quantification of the Mander’s colocalization coefficient (MCC) for the co-occurrence of TRAF6 antibody staining in IRAK1 clusters in iBMDMs. (F) PCC and (G) MCC for pTBK1 antibody staining in IRAK1 clusters. (H-K) Proximity ligation assay in iBMDMs. (H) IRAK1-TRAF6 PLA, (I) IRAK1-pTBK1 PLA, (J) IRAK2-TRAF6 PLA, (K) IRAK1-pTBK1 PLA. (L, M) Single or co-TLR stimulation of TLR4 and TLR1/2 with Kdo-2 Lipid A and P3C (50 nM each). Quantification of (L) pp65 nuclear translocation (M) pATF2 nuclear translocation. (N) Quantification of pATF2 nuclear translocation on co-TLR stimulation of TLR4 and TLR1/2 with Kdo-2 Lipid A and P3C ± 30 min pre-treatment with dynasore, an internalization inhibitor, 20 μ M, ST2825, a MyD88 dimerization inhibitor, 20 μ M, and thymoquinone, an IRAK1 kinase inhibitor, 25 μ M. (D-G) Data are represented as mean ± SD. (H-N) Data are represented as median ± MAD. (Panels D-G) Each data point represents value from a randomly selected non-over lapping field of cells. Paired t test. (Panels H-M) Tukey’s multiple comparisons test. (Panel N) Dunnett’s multiple comparisons test. p = 0.1234 (ns), 0.0332(*); 0.0021 (**); 0.0002 (***); < 0.0001 (****). Data shown are representative of at least two independent experiments.

Journal: bioRxiv

Article Title: IRAK1-mediated coincidence detection of microbial signals licenses inflammasome activation

doi: 10.1101/2019.12.26.888776

Figure Lengend Snippet: (A-K) Kdo-2 Lipid A and P3C co-treatment (50 nM each) in iBMDMs. Co-staining of IRAK1 clusters and (A) ßTrCp, (B) pellino, and (C) IRAK3. Scale Bar: 10 μ . (D) Quantification of the Pearson’s correlation coefficient (PCC) for the correlation of TRAF6 antibody staining in IRAK1 clusters. (E) Quantification of the Mander’s colocalization coefficient (MCC) for the co-occurrence of TRAF6 antibody staining in IRAK1 clusters in iBMDMs. (F) PCC and (G) MCC for pTBK1 antibody staining in IRAK1 clusters. (H-K) Proximity ligation assay in iBMDMs. (H) IRAK1-TRAF6 PLA, (I) IRAK1-pTBK1 PLA, (J) IRAK2-TRAF6 PLA, (K) IRAK1-pTBK1 PLA. (L, M) Single or co-TLR stimulation of TLR4 and TLR1/2 with Kdo-2 Lipid A and P3C (50 nM each). Quantification of (L) pp65 nuclear translocation (M) pATF2 nuclear translocation. (N) Quantification of pATF2 nuclear translocation on co-TLR stimulation of TLR4 and TLR1/2 with Kdo-2 Lipid A and P3C ± 30 min pre-treatment with dynasore, an internalization inhibitor, 20 μ M, ST2825, a MyD88 dimerization inhibitor, 20 μ M, and thymoquinone, an IRAK1 kinase inhibitor, 25 μ M. (D-G) Data are represented as mean ± SD. (H-N) Data are represented as median ± MAD. (Panels D-G) Each data point represents value from a randomly selected non-over lapping field of cells. Paired t test. (Panels H-M) Tukey’s multiple comparisons test. (Panel N) Dunnett’s multiple comparisons test. p = 0.1234 (ns), 0.0332(*); 0.0021 (**); 0.0002 (***); < 0.0001 (****). Data shown are representative of at least two independent experiments.

Article Snippet: Antibody pairs used for PLA in iBMDMs: IRAK1 Ms (SCBT sc-5288) and TRAF6 Rb (Bioss bs-1184R); IRAK1 Ms (SCBT sc-5288) and pTBK1 Rb (CST 5483S); IRAK1 Ms (SCBT sc-5288) and pTAB2 Rb (CST 8155S); IRAK2 Ms (SCBT sc-515885) and TRAF6 Rb (Bioss bs-1184R); IRAK2 Ms (SCBT sc-515885) and pTBK1 Rb (CST 5483S); IRAK2 Ms (SCBT sc-515885) and pTAB2 Rb (CST 8155S); IRAK1 Ms (SCBT sc-5288) and ASC Rb (SCBT sc-22514-R); IRAK1 Rb (CST 4504S) and NLRP3 Ms (AdipoGen AG-20B-0014-C100).

Techniques: Staining, Proximity Ligation Assay, Translocation Assay

Exaggerated inflammatory response in miR-146a –null mice. (A and B) Serum levels of TNF (A) and IL-6 (B) in miR-146a −/− ( n = 5; KO) and WT ( n = 6) animals challenged intraperitoneally with sublethal dose of LPS (1 mg/kg). Peripheral blood was drawn at the times indicated in the graphs, and cytokine concentrations were assessed by ELISA. Results are shown as means; data are representative of two independent experiments. P-value calculations were performed using Student’s t test. (C) Kaplan-Meier survival curves of miR-146a −/− (KO) and WT mice ( n = 12 for each group) challenged with a lethal dose of LPS (35 mg/kg). Results are representative of two independent experiments. P-value calculation was performed using log-rank (Mantel-Cox) test. (D and E) Production of TNF (D) and IL-6 (E) by miR-146a −/− (KO) and WT BMDMs in response to 10 ng/ml LPS challenge. Cells were stimulated for the indicated time, and cytokine concentrations were assessed by ELISA. Data are shown as mean ± SD. Results are representative of three independent experiments. (F and G) Western blot analysis of TRAF6 and IRAK1 protein expression in WT and miR-146a −/− (KO) BMDMs (F) and CD19 + splenic B cells (G). Numbers under the blots denote relative expression normalized to β-actin expression for each sample. Two mice per genotype were analyzed. Results are representative of two independent experiments. (H and I) Quantification of Western blots in F and G. Relative TRAF6 and IRAK1 expression in WT and KO BMDMs (H) and CD19 + splenic B cells (I) is plotted. Data from two mice for each genotype were averaged and are expressed as a ratio of protein expression in miR-146a KO to WT cells. All experiments were carried in the B6/ miR-146a −/− strain of mice.

Journal: The Journal of Experimental Medicine

Article Title: miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice

doi: 10.1084/jem.20101823

Figure Lengend Snippet: Exaggerated inflammatory response in miR-146a –null mice. (A and B) Serum levels of TNF (A) and IL-6 (B) in miR-146a −/− ( n = 5; KO) and WT ( n = 6) animals challenged intraperitoneally with sublethal dose of LPS (1 mg/kg). Peripheral blood was drawn at the times indicated in the graphs, and cytokine concentrations were assessed by ELISA. Results are shown as means; data are representative of two independent experiments. P-value calculations were performed using Student’s t test. (C) Kaplan-Meier survival curves of miR-146a −/− (KO) and WT mice ( n = 12 for each group) challenged with a lethal dose of LPS (35 mg/kg). Results are representative of two independent experiments. P-value calculation was performed using log-rank (Mantel-Cox) test. (D and E) Production of TNF (D) and IL-6 (E) by miR-146a −/− (KO) and WT BMDMs in response to 10 ng/ml LPS challenge. Cells were stimulated for the indicated time, and cytokine concentrations were assessed by ELISA. Data are shown as mean ± SD. Results are representative of three independent experiments. (F and G) Western blot analysis of TRAF6 and IRAK1 protein expression in WT and miR-146a −/− (KO) BMDMs (F) and CD19 + splenic B cells (G). Numbers under the blots denote relative expression normalized to β-actin expression for each sample. Two mice per genotype were analyzed. Results are representative of two independent experiments. (H and I) Quantification of Western blots in F and G. Relative TRAF6 and IRAK1 expression in WT and KO BMDMs (H) and CD19 + splenic B cells (I) is plotted. Data from two mice for each genotype were averaged and are expressed as a ratio of protein expression in miR-146a KO to WT cells. All experiments were carried in the B6/ miR-146a −/− strain of mice.

Article Snippet: Anti–mouse IRAK1 antibodies were obtained from Cell Signaling Technology, and anti-mouse TRAF6 were obtained from MBL International; anti–human IRAK1 and TRAF6 were purchased from Santa Cruz Biotechnology, Inc. Quantification of relative expression for each target protein was performed in Photoshop CS4 (Adobe), and β-actin levels were used for normalization.

Techniques: Enzyme-linked Immunosorbent Assay, Western Blot, Expressing

Ectopic expression of miR-146a in THP-1 cells results in attenuation of inflammatory response. (A and B) Production of TNF (A) and IL-6 (B) by THP-1 stable cell lines ectopically expressing either miR-146a (THP1/146) or scramble control sequence (THP1/SCR) in response to 1 µg/ml LPS stimulation. Cells were stimulated for the indicated time, and cytokines concentrations were assessed by ELISA. Results are shown as mean ± SD. Data are representative of two independent experiments. (C) Western blot analysis of TRAF6 and IRAK1 protein expression in THP1/146 and THP1/SCR clones stimulated or not with LPS, as indicated. Numbers under the blots denote relative expression normalized to β-actin expression for each sample. Data are representative of two independent experiments.

Journal: The Journal of Experimental Medicine

Article Title: miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice

doi: 10.1084/jem.20101823

Figure Lengend Snippet: Ectopic expression of miR-146a in THP-1 cells results in attenuation of inflammatory response. (A and B) Production of TNF (A) and IL-6 (B) by THP-1 stable cell lines ectopically expressing either miR-146a (THP1/146) or scramble control sequence (THP1/SCR) in response to 1 µg/ml LPS stimulation. Cells were stimulated for the indicated time, and cytokines concentrations were assessed by ELISA. Results are shown as mean ± SD. Data are representative of two independent experiments. (C) Western blot analysis of TRAF6 and IRAK1 protein expression in THP1/146 and THP1/SCR clones stimulated or not with LPS, as indicated. Numbers under the blots denote relative expression normalized to β-actin expression for each sample. Data are representative of two independent experiments.

Article Snippet: Anti–mouse IRAK1 antibodies were obtained from Cell Signaling Technology, and anti-mouse TRAF6 were obtained from MBL International; anti–human IRAK1 and TRAF6 were purchased from Santa Cruz Biotechnology, Inc. Quantification of relative expression for each target protein was performed in Photoshop CS4 (Adobe), and β-actin levels were used for normalization.

Techniques: Expressing, Stable Transfection, Control, Sequencing, Enzyme-linked Immunosorbent Assay, Western Blot, Clone Assay

FHL2 interacts with TRAF6 (A) Representative IF images of FHL2 and TRAF6 expression in kidney tissues (Scale bars, 100 μm). (B–C) The expression of TRAF6 and NF-κB pathway-related proteins in HK-2 cell lines after FHL2 overexpression was examined by Western blot. GAPDH was used as a loading control. (D) CoIP experiments validate the interaction between FHL2 and TRAF6. Data represent mean ± SDs, and statistical analysis was performed using one-way ANOVA. (∗ p < 0.05).

Journal: iScience

Article Title: ATF6 ameliorates renal warm ischemia-reperfusion injury through FHL2-mediated NF-κB signaling pathway

doi: 10.1016/j.isci.2026.115173

Figure Lengend Snippet: FHL2 interacts with TRAF6 (A) Representative IF images of FHL2 and TRAF6 expression in kidney tissues (Scale bars, 100 μm). (B–C) The expression of TRAF6 and NF-κB pathway-related proteins in HK-2 cell lines after FHL2 overexpression was examined by Western blot. GAPDH was used as a loading control. (D) CoIP experiments validate the interaction between FHL2 and TRAF6. Data represent mean ± SDs, and statistical analysis was performed using one-way ANOVA. (∗ p < 0.05).

Article Snippet: TRAF6 , Affinity Biosciences , Cat# AF5376; RRID: AB_2810280.

Techniques: Expressing, Over Expression, Western Blot, Control